BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22161982)

  • 1. [Vascular endothelial growth factor (VEGF) in endocrinology and oncology].
    Kajdaniuk D; Marek B; Fołtyn W; Kos-Kudła B
    Endokrynol Pol; 2011; 62 Suppl 3():14-22. PubMed ID: 22161982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor (VEGF) - part 2: in endocrinology and oncology.
    Kajdaniuk D; Marek B; Foltyn W; Kos-Kudła B
    Endokrynol Pol; 2011; 62(5):456-64. PubMed ID: 22069107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis in endocrine tumors.
    Turner HE; Harris AL; Melmed S; Wass JA
    Endocr Rev; 2003 Oct; 24(5):600-32. PubMed ID: 14570746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma.
    Zhang L; Yang N; Conejo-Garcia JR; Katsaros D; Mohamed-Hadley A; Fracchioli S; Schlienger K; Toll A; Levine B; Rubin SC; Coukos G
    Clin Cancer Res; 2003 Jan; 9(1):264-72. PubMed ID: 12538479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.
    Bunone G; Vigneri P; Mariani L; Butó S; Collini P; Pilotti S; Pierotti MA; Bongarzone I
    Am J Pathol; 1999 Dec; 155(6):1967-76. PubMed ID: 10595926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms.
    Abu-Jawdeh GM; Faix JD; Niloff J; Tognazzi K; Manseau E; Dvorak HF; Brown LF
    Lab Invest; 1996 Jun; 74(6):1105-15. PubMed ID: 8667614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
    Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
    Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma.
    Brown LF; Tognazzi K; Dvorak HF; Harrist TJ
    Am J Pathol; 1996 Apr; 148(4):1065-74. PubMed ID: 8644848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy.
    Zhang Y; Yang Y; Hosaka K; Huang G; Zang J; Chen F; Zhang Y; Samani NJ; Cao Y
    Proc Natl Acad Sci U S A; 2016 Apr; 113(15):4158-63. PubMed ID: 27035988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway.
    Kim DS; Franklyn JA; Boelaert K; Eggo MC; Watkinson JC; McCabe CJ
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4603-11. PubMed ID: 16926250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features.
    La Rosa S; Uccella S; Finzi G; Albarello L; Sessa F; Capella C
    Hum Pathol; 2003 Jan; 34(1):18-27. PubMed ID: 12605362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis.
    García-Quiroz J; Rivas-Suárez M; García-Becerra R; Barrera D; Martínez-Reza I; Ordaz-Rosado D; Santos-Martinez N; Villanueva O; Santos-Cuevas CL; Avila E; Gamboa-Domínguez A; Halhali A; Larrea F; Díaz L
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():215-22. PubMed ID: 24120914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis in endocrine glands: special reference to the expression of vascular endothelial growth factor.
    Katoh R
    Microsc Res Tech; 2003 Feb; 60(2):181-5. PubMed ID: 12539172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [VEGF in neoplastic angiogenesis].
    Chekhonin VP; Shein SA; Korchagina AA; Gurina OI
    Vestn Ross Akad Med Nauk; 2012; (2):23-33. PubMed ID: 22642175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
    Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
    Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
    Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
    Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.